LearnGlossaryMarketStocksSuperinvestorsSign in

AKTS

Aktis Oncology, Inc.

Healthcare · $1.0B market cap

Verdict

We can't put a fair value on AKTS right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth—?
Sales growth336.9% a year✓
Free cash flow growth—?
Return on invested capital-26.1%✗

Follow AKTS

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds AKTS. In Q2 2026, 1 opened a position. Who we track

Polen Capital Management

Polen Capital Management · as of Q2 2026

$2.0M

63,514 shares

Moves in Q2 2026

New position: Polen Capital Management

About Aktis Oncology, Inc.

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works